GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

GSK has agreed to pay up to $2.2 billion to settle most pending U.S. state court lawsuits claiming that a discontinued ...

Shares of GSK rose as much as 6.5% on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle ...

The deal settles 80,000 US court cases related to allegations that Zantac was contaminated with a suspected carcinogen.

British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...

GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...

GSK has agreed to pay $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac ...

GSK has agreed to a $2.2 billion settlement to resolve the majority of U.S. state court Zantac lawsuits, with an additional ...

The pharmaceutical giant has settled the vast majority of cases around its drug Zantac in the US, boosting investor ...

The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.

The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.